News Column

Findings in the Area of Cancer Gene Therapy Reported from General Hospital (Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles...

August 4, 2014



Findings in the Area of Cancer Gene Therapy Reported from General Hospital (Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy)

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting originating in Shandong, People's Republic of China, by NewsRx journalists, research stated, "The co-delivery of DNA and antitumor drugs has the potential to treat cancer. In this study, we aimed to develop surface-modified, co-encapsulated solid lipid nanoparticles (SLN) containing enhanced green fluorescence protein plasmid (pEGFP) and doxorubicin (DOX) in order to create a multifunctional delivery system that targets lung cancer cells, in an effort to improve the efficacy of cancer therapy."

The news reporters obtained a quote from the research from General Hospital, "DOX-and pEGFP-loaded SLN were prepared separately and then mixed to form co-encapsulated SLN (SLN/DE). Transferrin (Tf)-containing ligands were used for the surface coating of the vectors. The in vitro transfection efficiency of the modified vectors was evaluated using a human alveolar adenocarcinoma cell line (A549 cells) and the in vivo transfection efficiency of the modified vectors was evaluated using mice bearing A549 tumors. The Tf-modified DOX and pEGFP co-encapsulated SLN (T-SLN/DE) had a particle size of 267 nm with a 42 mV surface charge. The in vitro cytotoxicity of T-SLN/DE was low (cell viability was between 80 and 100% compared with the controls). T-SLN/DE displayed a remarkable therapeutic effect both in drug delivery and gene therapy."

According to the news reporters, the research concluded: "Our results demonstrate that the multifunctional delivery system can improve the efficacy of cancer therapy through the combination of gene therapy and chemotherapy. In addition, the coating of active targeting ligands can improve the efficacy of the carriers at targeting lung cancer cells. Thus, the novel gene and drug delivery system offers an effective strategy for lung cancer gene therapy."

For more information on this research see: Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. International Journal of Molecular Medicine, 2014;34(1):191-6 (see also Biotechnology).

Our news correspondents report that additional information may be obtained by contacting Y. Han, Dept. of Respiratory Medicine, General Hospital of Ji'nan Command of Chinese PLA, Ji'nan, Shandong 250031, People's Republic of China. Additional authors for this research include P. Zhang, Y. Chen, J. Sun and F. Kong.

Keywords for this news article include: Asia, Biotechnology, Shandong, Oncology, Lung Cancer, Nanoparticle, Lung Neoplasms, Nanotechnology, Cancer Gene Therapy, Emerging Technologies, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters